Unknown

Dataset Information

0

Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance).


ABSTRACT: OBJECTIVES:While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for older adults (aged ?70years) with advanced colorectal cancer. Here we review the challenges faced and reasons for poor accrual to N0949. MATERIALS AND METHODS:We describe the conceptualization, development and limited results of N0949, a randomized phase III study of fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer. Fluoropyrimidine was physician choice (e.g., 5-FU/LV or capecitabine). RESULTS:Of the projected 380 patients, only 32 patients were enrolled between the study activation in January 2011 until its closure in September 2012. Reasons for poor accrual included eligibility criteria that were too stringent, discomfort with randomizing older patients to regimens of varying intensity without considering their physical fitness, and discomfort with the use of bevacizumab in the older patient population. Several efforts were mounted to design a rationale and age-appropriate study, consider toxicities and varying study practices, and be responsive to stakeholder feedback. CONCLUSIONS:Challenges were experienced in conducting the first prospective phase III study evaluating progression-free survival of older adults with advanced colorectal cancer receiving palliative chemotherapy with fluoropyrimidine/bevacizumab with or without oxaliplatin in the USA. Future efforts to evaluate treatment outcomes in the older adult population should reflect on lessons learned in this large national effort.

SUBMITTER: McCleary NJ 

PROVIDER: S-EPMC5757827 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance).

McCleary Nadine J NJ   Hubbard Joleen J   Mahoney Michelle R MR   Meyerhardt Jeffrey A JA   Sargent Daniel D   Venook Alan A   Grothey Axel A  

Journal of geriatric oncology 20170913 1


<h4>Objectives</h4>While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for older adults (aged ≥70years) with advanced colorectal cancer. Here we review the challenges faced and reasons for poor accrual to N0949.<h4>Materials and methods</h4>We describe the conceptualization, development and limited results of N0949, a  ...[more]

Similar Datasets

| S-EPMC10523847 | biostudies-literature
| S-EPMC3935288 | biostudies-literature
| S-EPMC3662843 | biostudies-literature
| S-EPMC9869607 | biostudies-literature
| S-EPMC10719521 | biostudies-literature
| S-EPMC8491412 | biostudies-literature
| S-EPMC6133718 | biostudies-literature
| S-EPMC6440868 | biostudies-literature
| S-EPMC4583740 | biostudies-literature
| S-EPMC4980566 | biostudies-literature